Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KIF5B | P33176 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577687 | 0.88 | ABCG2 (0.38) | SMN1; SMN2ALDH1A1TSHRABCG2PDE5A | |
| SCHEMBL23577241 | 0.87 | MAPT (0.43) | SMN1; SMN2ALDH1A1TSHRABCG2PDE5A | |
| SCHEMBL23577080 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2KDRTSHRPDE5AALOX15 | |
| SCHEMBL30961004 | 0.86 | PDE5A (0.44) | SMN1; SMN2KDRTSHRPDE5AALOX15 | |
| SCHEMBL23577222 | 0.86 | PDE5A (0.44) | SMN1; SMN2KDRTSHRPDE5AALOX15 | |
| SCHEMBL23578033 | 0.86 | PDE5A (0.44) | SMN1; SMN2ALDH1A1TSHRABCG2PDE5A | |
| SCHEMBL23601315 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1TSHRABCG2PDE5A | |
| SCHEMBL23577658 | 0.86 | PDGFRB (0.42) | SMN1; SMN2KDRTSHRABCG2PDE5A | |
| SCHEMBL23576623 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2KDRTSHRABCG2PDE5A | |
| SCHEMBL23577954 | 0.86 | FNTA (0.41) | SMN1; SMN2ABCG2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | SMN1; SMN2 4737/4885RET 1423/4885KIF5B 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.